Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Caroline Arber; Gabriela Baerlocher; Yves Chalandon; Michael Daskalakis; Michel Duchosal; Martin Fehr; Sabine Gerull; Tayfun Güngör; Gayathri Nair; Thomas Pabst; Jakob R. Passweg; Barbara Piccolruaz; Christoph Renner; Axel Ruefer; Dominik Schneidawind; Georg Stüssi; Sacha Zeerleder; Jörg P. Halter

doi:10.57187/s.3704

Technical comment

Vol. 154 No. 10 (2024)

Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Caroline Arber⁺⁻
Gabriela Baerlocher
Yves Chalandon
Michael Daskalakis
Michel Duchosal
Martin Fehr
Sabine Gerull
Tayfun Güngör
Gayathri Nair
Thomas Pabst
Jakob R. Passweg
Barbara Piccolruaz
Christoph Renner
Axel Ruefer
Dominik Schneidawind
Georg Stüssi
Sacha Zeerleder
Jörg P. Halter

DOI: https://doi.org/10.57187/s.3704
Cite this as:: Swiss Med Wkly. 2024;154:3704
Published: 03.10.2024

Summary

No abstract available.

References

Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2023 Sep;153(9):3441. doi: https://doi.org/10.57187/s.3441 DOI: https://doi.org/10.57187/s.3441
Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol. 2024 Jan;42(1):e3241. doi: https://doi.org/10.1002/hon.3241 DOI: https://doi.org/10.1002/hon.3241
Duchosal MA, et al. Développements récents en hématologie, Teil 1. Swiss Medical Forum, 2023. doi: https://doi.org/10.4414/fms.2023.09462 DOI: https://doi.org/10.4414/fms.2023.09462
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56. doi: https://doi.org/10.1056/NEJMoa1804980 DOI: https://doi.org/10.1056/NEJMoa1804980
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec;377(26):2531–44. doi: https://doi.org/10.1056/NEJMoa1707447 DOI: https://doi.org/10.1056/NEJMoa1707447
Di Blasi R, Thieblemont C, Haioun C, Sackmann Sala L, Mayaud AC, Diez-Andreu P, et al. Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI. Value Health. 2022;25(12):S79–80. doi: https://doi.org/10.1016/j.jval.2022.09.390 DOI: https://doi.org/10.1016/j.jval.2022.09.390
Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html

How to Cite

1.

Arber C, Baerlocher G, Chalandon Y, Daskalakis M, Duchosal M, Fehr M, Gerull S, Güngör T, Nair G, Pabst T, Passweg JR, Piccolruaz B, Renner C, Ruefer A, Schneidawind D, Stüssi G, Zeerleder S, Halter JP. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly [Internet]. 2024 Oct. 3 [cited 2024 Dec. 3];154(10):3704. Available from: https://smw.ch/index.php/smw/article/view/3704

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

Adalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, Aju P. Pazhenkottil, Paolo Arosio, Manuela Averaimo, Ulrike Bacher, Peter Bode, Andrea Cavalli, Stefan Dirnhofer, Nadia Djerbi, Stephan Dobner, Thomas Fehr, Maura Garofalo, Ariana Gaspert, Sabine Gerull, Raphael Heimgartner, Annemarie Hübers, Hans H. Jung, Chiara Kessler, Raphael Knöpfel, Natallia Laptseva, Giulia Magini, Robert Manka, Luca Mazzucchelli, Martin Meyer, Violeta Mihaylova, Pierre Monney, Alessio Mylonas, René Nkoulou, Thomas Pabst, Otmar Pfister, Axel Rüfer, Adrian Schmidt, Harald Seeger, Simon F. Stämpfli, Guido Stirnimann, Thomas Suter, Giorgio Treglia, Alexandar Tzankov, Friederike Vetter, Markus Zweier, Andreas J. Flammer, Bernhard Gerber, Management of transthyretin amyloidosis , Swiss Medical Weekly: Vol. 151 No. 4142 (2021)
Rahel Schwotzer, Andreas J. Flammer, Sabine Gerull, Thomas Pabst, Paolo Arosio, Manuela Averaimo, Ulrike Bacher, Peter Bode, Andrea Cavalli, Adalgisa Condoluci, Stefan Dirnhofer, Nadia Djerbi, Stephan W. Dobner, Thomas Fehr, Maura Garofalo, Ariana Gaspert, Raphael Heimgartner, Annemarie Hübers, Hans H. Jung, Chiara Kessler, Raphael Knöpfel, Natallia Laptseva, Robert Manka, Luca Mazzucchelli, Martin Meyer, Violeta Mihaylova, Pierre Monney, Alessio Mylonas, René Nkoulou, Aju P. Pazhenkottil, Otmar Pfister, Axel Rüfer, Adrian Schmidt, Harald Seeger, Simon F. Stämpfli, Guido Stirnimann, Thomas Suter, Marie Théaudin, Giorgio Treglia, Alexandar Tzankov, Friederike Vetter, Markus Zweier, Bernhard Gerber, Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis , Swiss Medical Weekly: Vol. 150 No. 4950 (2020)
Johannes Trück, Seraina Prader, Giancarlo Natalucci, Cornelia Hagmann, Barbara Brotschi, Janet Kelly, Dirk Bassler, Katharina Steindl, Anita Rauch, Matthias Baumgartner, Ralph Fingerhut, Mathias Hauri-Hohl, Tayfun Güngör, Jana Pachlopnik Schmid, Christoph Berger, Janine Reichenbach, Swiss newborn screening for severe T and B cell deficiency with a combined TREC/KREC assay – management recommendations , Swiss Medical Weekly: Vol. 150 No. 2526 (2020)
Jakob R. Passweg, Helen Baldomero, Marc Ansari, Gabriela M. Baerlocher, Mario Bargetzi, Yves Chalandon, Michel A. Duchosal, Sabine Gerull, Tayfun Güngör, Jörg P. Halter, Dominik Heim, Urs Hess, Kurt Leibundgut, Stavroula Masouridi-Levrat, Antonia Müller, Gayathri Nair, Thomas Pabst, Christoph Renner, Adrian Schmidt, Georg Stussi, Grazia Nicoloso de Faveri, Urs Schanz, for the Swiss Blood Stem Cell Transplantation Group (SBST), Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016 , Swiss Medical Weekly: Vol. 148 No. 0910 (2018)
Dominik Heim, Helen Baldomero, Michael Medinger, Stavroula Masouridi-Levrat, Urs Schanz, Gayathri Nair, Tayfun Güngör, Jörg Halter, Jakob R. Passweg, Yves Chalandon, Swiss Stem Cell Transplantation Group (SBST), Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs , Swiss Medical Weekly: Vol. 154 No. 5 (2024)
Sofie Brouwers, Raphael Heimgartner, Natallia Laptseva, Adriano Aguzzi, Niklas F. Ehl, Thomas Fehr, Felicitas Hitz, Hans H. Jung, Joel Kälin, Markus G. Manz, Beat Müllhaupt, Frank Ruschitzka, Harald Seeger, Georg Stussi, Markus Zweier, Andreas J. Flammer, Bernhard Gerber, Rahel Schwotzer, Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry , Swiss Medical Weekly: Vol. 154 No. 2 (2024)
Rüdiger Müller, Christoph Renner, Cem Gabay, Giuseppe Cassata, Andreas Lohri, Paul Hasler, The advent of biosimilars: challenges and risks , Swiss Medical Weekly: Vol. 144 No. 2728 (2014)
Ulrich J. M. Mey, Felicitas Hitz, Andreas Lohri, Stefanie Pederiva, Christian Taverna, Alexander Tzankov, Oliver Meier, Karen Yeow, Christoph Renner, Diagnosis and treatment of diffuse large B-cell lymphoma , Swiss Medical Weekly: Vol. 142 No. 0506 (2012)
Mario Bargetzi, Reto Baumann, Sergio Cogliatti, Pierre-Yves Dietrich, Michel André Duchosal, Jeroen S. Goede, Felicitas Hitz, Carolin Konermann, Andreas Lohri, Ulrich Mey, Urban Novak, Alexandros Papachristofilou, Frank Stenner, Christian Taverna, Thilo Zander, Christoph Renner, Diagnosis and treatment of follicular lymphoma: an update , Swiss Medical Weekly: Vol. 148 No. 2930 (2018)
Jakob Passweg, Helen Baldomero, Mario Bargetzi, Christoph Bucher, Yves Chalandon, Michel A. Duchosal, Alois Gratwohl, Tayfun Güngör, Urs Hess, Kurt Leibundgut, Grazia Nicoloso de Faveri, Hulya Ozsahin, Thomas Pabst, Christoph Renner, Martin Stern, Georg Stussi, Urs Schanz, for the SBST (Swiss Blood Stem Cell Transplantation Group), Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries , Swiss Medical Weekly: Vol. 143 No. 0708 (2013)

1 2 3 > >>

[1] Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2023 Sep;153(9):3441. doi: https://doi.org/10.57187/s.3441 DOI: https://doi.org/10.57187/s.3441

[2] Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol. 2024 Jan;42(1):e3241. doi: https://doi.org/10.1002/hon.3241 DOI: https://doi.org/10.1002/hon.3241

[3] Duchosal MA, et al. Développements récents en hématologie, Teil 1. Swiss Medical Forum, 2023. doi: https://doi.org/10.4414/fms.2023.09462 DOI: https://doi.org/10.4414/fms.2023.09462

[4] Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56. doi: https://doi.org/10.1056/NEJMoa1804980 DOI: https://doi.org/10.1056/NEJMoa1804980

[5] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec;377(26):2531–44. doi: https://doi.org/10.1056/NEJMoa1707447 DOI: https://doi.org/10.1056/NEJMoa1707447

[6] Di Blasi R, Thieblemont C, Haioun C, Sackmann Sala L, Mayaud AC, Diez-Andreu P, et al. Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI. Value Health. 2022;25(12):S79–80. doi: https://doi.org/10.1016/j.jval.2022.09.390 DOI: https://doi.org/10.1016/j.jval.2022.09.390

[7] Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html